The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pilot-study.
K. El Khalfaoui
No relevant relationships to disclose
S. Mahner
No relevant relationships to disclose
R. Richter
No relevant relationships to disclose
F. Hilpert
No relevant relationships to disclose
R. Lorenz
No relevant relationships to disclose
P. Harter
No relevant relationships to disclose
P. Klare
No relevant relationships to disclose
U. A. G. Wagner
No relevant relationships to disclose
R. Chekerov
No relevant relationships to disclose
J. Sehouli
No relevant relationships to disclose